Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Table 2 Previous and concomitant medications (analysis population)

Treatment parameter	N = 865
Previous treatments
Number of prior DMARDs	N = 865
0–3, n (%)	582 (67.3)
>3, n (%)	283 (32.7)
Number of prior anti-TNF agents	N = 865
≥2, n (%)	429 (49.6)
<2, n (%)	436 (50.4)
Type of biologic agent	N = 851
Other MOA, n (%)	134 (15.8)
Anti-TNF agent	717 (84.3)
Reason for discontinuation of last biologic	N = 847
Intolerance, n (%)	190 (22.4)
Primary inefficacy, n (%)^a	203 (24.0)
Secondary inefficacy, n (%)^†	400 (47.2)
Major improvement + other reasons, n (%)	54 (6.4)
Concomitant therapies
Abatacept treatment pattern at initiation	N = 865
Monotherapy, n (%)	201 (23.2)
Combination with MTX (± other DMARDs), n (%)	483 (55.8)
Combination with other DMARDs, n (%)	181 (20.9)
Corticosteroid treatment pattern at abatacept initiation (versus before initiation)^‡	N = 865
No corticosteroids, n (%)	202 (25.4)
Continuous use of corticosteroids, n (%)	491 (56.8)
Stop corticosteroid use, n (%)	18 (2.1)
Introduction of corticosteroids, n (%)	154 (17.8)

Category in italics is the reference for univariate and multivariate analyses
The analysis population included patients treated in Canada, Germany, Greece, and Italy who had received at least one prior biologic agent and had a baseline clinical assessment no later than 8 days after the first administration of abatacept. Patient population includes 17 patients who did not receive prior treatment with an anti-TNF agent but a biologic agent with another MOA
DMARD disease-modifying anti-rheumatic drug, MOA mechanism of action, MTX methotrexate, TNF tumor necrosis factor
^aFailure to respond; ^†Loss of efficacy after initial response. ^‡Mean (standard deviation) corticosteroid dose was 8.73 (11.62) mg/day in patients who continued use of corticosteroids or who started corticosteroids at abatacept initiation (n = 645)